

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2022 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the financial year 2022. This announcement and the accompanying financial statements were originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 25, 2022

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.

Hangzhou Tigermed Consulting Co., Ltd.
2022 THIRD QUARTERLY REPORT

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and there is no false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.
2. The head of the Company, person-in-charge of accounting affairs and head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
3. Whether the third quarterly report is audited.

☐ Yes ☒ No

I. KEY FINANCIAL DATA

(I) Major accounting data and financial indicators

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

☐ Yes ☒ No

	Reporting Period	Change	From the beginning of the year to the end of the Reporting Period	Change
Revenue (RMB)	1,811,809,605.48	35.35%	5,406,018,843.59	59.23%
Net profit attributable to shareholders of the listed company (RMB)	412,654,717.12	-21.56%	1,604,658,753.47	-9.90%
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss (RMB)	420,730,911.64	29.02%	1,192,106,545.36	37.20%
Net cash flows from operating activities (RMB)	—	—	825,385,230.87	13.31%
Basic earnings per share (RMB/share)	0.48	-20.00%	1.86	-9.27%
Diluted earnings per share (RMB/share)	0.48	-20.00%	1.86	-8.82%
Weighted average return on net assets	2.18%	-0.86%	8.60%	-2.02%
	End of the Reporting Period		End of prior year	Change
Total assets (RMB)	27,140,006,778.09		23,741,171,551.32	14.32%
Owners' equity attributable to shareholders of the listed company (RMB)	19,191,149,788.80		18,123,626,117.21	5.89%

(II) Items and amounts of extraordinary gain or loss

√ Applicable □ Not applicable

Unit: RMB

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for impairment of assets)	-9,589,917.21	25,500,766.31	Mainly due to the disposal of long-term assets including long-term equity investments and fixed assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business scope of the Company and entitled in standard amounts or quantities in conformity with the provisions of policies of the State) included in the profit or loss for the period	8,618,487.36	12,790,639.46	Mainly due to the government grants received by the Company during the Reporting Period.
Gain from the excess of the fair value of the identifiable net assets of investees on acquisition of the investment over the investment cost in the Company's subsidiaries, associates and joint ventures	13,552,781.21	13,552,781.21	Mainly due to the investment income of the Company arising from the consolidation of subsidiaries during the Reporting Period.
Gain or loss from investments on trust or asset management	209,924.11	900,180.65	Mainly due to the income from wealth management products of the Company during the Reporting Period.
Profit or loss arising from changes in fair value of held-for-trading financial assets, held-for-trading financial liabilities and investment income received from disposal of held-for-trading financial assets, held-for-trading financial liabilities and available-for-sale financial assets (except for those related to effective hedging businesses under ordinary business scope of the Company)	-8,756,319.09	455,075,355.66	Mainly due to the investment income recognized from the holding and disposal of other non-current financial assets, and gains from changes in fair value of other non-current financial assets during the Reporting Period.
Other non-operating income and expenses apart from the above items	-292,444.67	-3,059,195.12	
Less: Effect of income tax	-817,169.27	7,485,608.38	
Effect of non-controlling interests (after tax)	12,635,875.50	84,722,711.68	
Total	-8,076,194.52	412,552,208.11	–

Details of other profit or loss items meeting the definition of extraordinary gain or loss:

☐ Applicable ☒ Not applicable

There was no other profit or loss items that meet the definition of extraordinary gain or loss.

Explanation on extraordinary gain or loss items defined as recurring gain or loss items as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss

☐ Applicable ☒ Not applicable

There was no item of extraordinary gain or loss defined as item of recurring gain or loss as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss.

(III) Changes in key accounting data and financial indicators and the reasons thereof

☒ Applicable ☐ Not applicable

I. Explanation of anomalies for balance sheet items and the reasons thereof

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Notes receivable	9,685,880.73	6,930,211.19	39.76%	Mainly due to the receipt of bank acceptance notes by the Company from customers during the Reporting Period.
Prepayments	82,031,728.54	59,293,798.01	38.35%	Mainly due to the increase in prepayments for materials and services by the Company during the Reporting Period.
Inventories	35,093,313.34	6,095,078.95	475.76%	Mainly due to the procurement of experimental materials by the Company during the Reporting Period.

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Contract assets	2,079,924,203.30	1,285,474,618.80	61.80%	Mainly due to the increase in the Company's operating income and the year-on-year increase in contract assets during the Reporting Period.
Other current assets	104,769,000.05	53,741,955.45	94.95%	Mainly due to the increase in tax prepayment by the Company during the Reporting Period.
Long-term equity investments	1,730,862,925.56	738,799,229.15	134.28%	Mainly due to the increase in investment in associates by the Company during the Reporting Period.
Other equity instruments investment	–	13,530,837.60	-100.00%	Mainly due to the increase in investment of the Company and the other equity instruments investment transferred to the consolidated subsidiaries during the Reporting Period.
Goodwill	2,502,676,842.64	1,778,947,124.71	40.68%	Mainly due to the increase in goodwill of the Company arising from the consolidation of subsidiaries during the Reporting Period.
Long-term deferred expenses	165,349,393.38	35,196,585.89	369.79%	Mainly due to the transfer-in of construction in progress of the Company during the Reporting Period.

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Short-term borrowings	2,100,267,574.00	492,320,000.00	326.61%	Mainly due to the increase in short-term borrowings from banks by the Company during the Reporting Period.
Notes payable	–	22,118,000.00	-100.00%	Mainly due to the settlement of the Company's bank acceptance notes during the Reporting Period.
Accounts payable	193,028,925.74	125,748,622.26	53.50%	Mainly due to the increase in payables for materials and services by the Company during the Reporting Period.
Other payables	83,532,652.21	155,704,656.83	-46.35%	Mainly due to the unlocking of the restricted shares of the Company during the Reporting Period.
Non-current liabilities due within one year	190,653,151.11	290,298,339.24	-34.33%	Mainly due to the Company's payment for minority shareholders' equity transfer during the Reporting Period.
Treasury stock	869,336,804.33	567,553,404.57	53.17%	Mainly due to the share repurchase by the Company during the Reporting Period.
Other comprehensive income	108,968,679.69	-155,992,714.24	-169.85%	Mainly due to the currency translation difference during the Reporting Period.

II. Explanation of anomalies for income statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Operating income	5,406,018,843.59	3,395,015,172.83	59.23%	Mainly due to the increase in customer needs and multi-regional clinical trials related to COVID-19 during the Reporting Period.
Operating cost	3,237,445,384.18	1,807,291,869.07	79.13%	Mainly due to the increase in the Company's operating income, the year-on-year increase in the Company's operating costs and the increase in the Company's payments to third-party suppliers during the Reporting Period.
Finance expenses	-118,911,951.41	-175,590,189.04	-32.28%	Mainly due to increase in interest expense on increased Company's short-term borrowings and decrease in interest income from the proceeds from H shares offering of the Company during the Reporting Period.
Other income	17,516,717.29	8,382,915.17	108.96%	Mainly due to the increase in government grants received by the Company during the Reporting Period.
Gain from fair value change	402,587,783.41	1,117,343,694.68	-63.97%	Mainly due to the decrease in gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-18,423,588.03	-6,071,755.06	203.43%	Mainly due to the increase in the provision for bad debts of receivables and other receivables by the Company during the Reporting Period.

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Asset impairment loss	-26,587,375.66	-11,726,611.79	126.73%	Mainly due to the increase in the provision for bad debts of contract assets by the Company during the Reporting Period.
Gains on disposal of assets	-24,769.40	-567,076.49	-95.63%	Mainly due to the decrease in disposal of long-term assets by the Company during the Reporting Period.
Non-operating income	11,032,473.26	2,433,020.50	353.45%	Mainly due to the increase in government grants received by the Company during the Reporting Period.
Income tax expenses	233,766,699.72	150,182,232.76	55.66%	Mainly due to the increase in operating profit after deducting the gains from changes in fair value and the year-on-year increase in income tax expenses during the Reporting Period.

III. Explanation of anomalies for cash flow statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Net cash flows from financing activities	793,767,270.67	-146,289,027.23	-642.60%	Mainly due to the increase in short-term borrowings of the Company during the Reporting Period.

II. SHAREHOLDERS' INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored and the shareholding of top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	45,457	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	0
---	--------	---	---

Shareholding of top 10 shareholders

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged, marked or frozen shares Share status	Quantity
Ye Xiaoping	Domestic natural person	20.32%	177,239,541	132,929,656		
HKSCC NOMINEES LIMITED	Overseas legal person	14.11%	123,119,479	0		
Hong Kong Securities Clearing Company Limited	Overseas legal person	10.66%	92,967,980	0		
Cao Xiaochun	Domestic natural person	6.55%	57,161,774	42,871,330	Pledged	20,600,000
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	4.21%	36,716,074	0		
TEMASEK FULLERTON ALPHA PTE LTD	Overseas legal person	2.24%	19,535,626	0		
Shi Xiaoli	Domestic natural person	1.30%	11,306,159	0	Pledged	2,728,268
ZHUAN YIN	Overseas natural person	1.18%	10,296,000	7,722,000		
Bank of China Limited - CMF CNI Biomedicine Index Classified Securities Investment Fund	Others	1.10%	9,610,686	0		
Bank of China Limited - Huabao CSI Medical Trading Open-End Index Securities Investment Fund	Others	1.03%	8,957,150	0		

Shareholding of the top 10 shareholders not subject to selling restrictions

Name of shareholder	Number of shares held not subject to selling restrictions	Share type	Quantity
HKSCC NOMINEES LIMITED	123,119,479	Overseas listed foreign shares	123,119,479
Hong Kong Securities Clearing Company Limited	92,967,980	Renminbi ordinary shares	92,967,980
Ye Xiaoping	44,309,885	Renminbi ordinary shares	44,309,885
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	36,716,074	Renminbi ordinary shares	36,716,074
TEMASEK FULLERTON ALPHA PTE LTD	19,535,626	Renminbi ordinary shares	19,535,626
Cao Xiaochun	14,290,444	Renminbi ordinary shares	14,290,444
Shi Xiaoli	11,306,159	Renminbi ordinary shares	11,306,159
Bank of China Limited - CMF CNI Biomedicine Index Classified Securities Investment Fund	9,610,686	Renminbi ordinary shares	9,610,686
Bank of China Limited - Huabao CSI Medical Trading Open-End Index Securities Investment Fund	8,957,150	Renminbi ordinary shares	8,957,150
Industrial and Commercial Bank of China Limited – IGW Emerging Growth Hybrid Securities Investment Fund	7,988,475	Renminbi ordinary shares	7,988,475

Explanation of the shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.
--	---

Description of top 10 shareholders participating in the margin trading business (if any)	Nil
--	-----

(II) Total number of preferred shareholders of the Company and the shareholding of top 10 preferred shareholders

☐ Applicable ☒ Not applicable

(III) Changes in restricted shares

√ Applicable □ Not applicable

Unit: share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares unlocked during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Cao Xiaochun	42,871,330	0	0	42,871,330	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
ZHUAN YIN	7,722,000	0	0	7,722,000	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Li Xiaori	11,058	0	0	11,058	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Total	183,534,044	0	0	183,534,044		

III. OTHER SIGNIFICANT EVENTS

□ Applicable √ Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) FINANCIAL STATEMENTS

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

September 30, 2022

Unit: RMB

Item	September 30, 2022	January 1, 2022
Current assets:		
Cash at bank and on hand	7,749,592,762.46	8,544,356,169.94
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	30,999,944.83	29,180,000.00
Derivative financial assets		
Notes receivable	9,685,880.73	6,930,211.19
Accounts receivable	886,252,793.72	809,126,538.78
Accounts receivable financing		
Advances to suppliers	82,031,728.54	59,293,798.01
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	56,105,611.06	57,602,385.75
Including: Interests receivable	6,973,454.59	6,665,602.38
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	35,093,313.34	6,095,078.95
Contract assets	2,079,924,203.30	1,285,474,618.80
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	104,769,000.05	53,741,955.45
Total current assets	11,034,455,238.03	10,851,800,756.87

Item	September 30, 2022	January 1, 2022
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	1,730,862,925.56	738,799,229.15
Other equity instruments investment		13,530,837.60
Other non-current financial assets	9,899,619,203.36	8,746,343,607.00
Investment properties		
Fixed assets	568,011,767.64	437,992,148.47
Construction in progress	161,047,467.96	217,141,355.50
Bearer biological assets		
Oil and gas assets		
Right-of-use assets	579,867,596.51	468,243,866.82
Intangible assets	312,543,142.52	250,635,355.97
Development disbursements		
Goodwill	2,502,676,842.64	1,778,947,124.71
Long-term deferred expenses	165,349,393.38	35,196,585.89
Deferred tax assets	108,517,024.81	100,935,511.86
Other non-current assets	77,056,175.68	101,605,171.48
Total non-current assets	16,105,551,540.06	12,889,370,794.45
Total assets	27,140,006,778.09	23,741,171,551.32

Item	September 30, 2022	January 1, 2022
Current liabilities:		
Short-term borrowings	2,100,267,574.00	492,320,000.00
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable		22,118,000.00
Accounts payable	193,028,925.74	125,748,622.26
Advanced receipts		
Contract liabilities	999,814,402.82	789,508,933.95
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	260,247,698.48	256,194,429.01
Tax payable	231,171,856.56	280,821,486.87
Other payables	83,532,652.21	155,704,656.83
Including: Interests payable	5,110,081.62	555,367.65
Dividends payable	1,843,323.65	3,199,519.60
Fees and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	190,653,151.11	290,298,339.24
Other current liabilities		
Total current liabilities	4,058,716,260.92	2,412,714,468.16

Item	September 30, 2022	January 1, 2022
Non-current liabilities:		
Reserve of insurance contract		
Long-term borrowings	69,376,658.50	
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	506,586,419.63	406,838,855.96
Long-term payables	83,063,669.91	114,881,345.42
Long-term employee benefits payable		
Provisions		
Deferred revenue	15,184,274.52	
Deferred tax liabilities	212,921,019.33	201,539,682.14
Other non-current liabilities		
Total non-current liabilities	887,132,041.89	723,259,883.52
Total liabilities	4,945,848,302.81	3,135,974,351.68
Owners' equity:		
Share capital	872,418,220.00	872,438,364.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital surplus	11,818,797,107.68	11,886,627,087.98
Less: Treasury stock	869,336,804.33	567,553,404.57
Other comprehensive income	108,968,679.69	-155,992,714.24
Special reserve		
Surplus reserve	317,385,421.14	317,385,421.14
General risk provision		
Retained earnings	6,942,917,164.62	5,770,721,362.90
Total equity attributable to owners of the parent	19,191,149,788.80	18,123,626,117.21
Non-controlling interests	3,003,008,686.48	2,481,571,082.43
Total owners' equity	22,194,158,475.28	20,605,197,199.64
Total liabilities and owners' equity	27,140,006,778.09	23,741,171,551.32

Legal representative:
Cao Xiaochun

*Person-in-charge of
accounting:*
Yang Chengcheng

*Head of accounting
department:*
Yang Chengcheng

2. Consolidated income statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Total revenue	5,406,018,843.59	3,395,015,172.83
Including: Operating income	5,406,018,843.59	3,395,015,172.83
Interest income		
Premium earned		
Fees and commission income		
II. Total cost of sales	3,872,546,448.56	2,286,708,012.11
Including: Operating cost	3,237,445,384.18	1,807,291,869.07
Interest expenses		
Fees and commission expenses		
Cash surrender value		
Claim settlement expenses, net		
Net provision of insurance contract liabilities		
Policy dividend expense		
Reinsurance expenses		
Business tax and surcharge	13,821,668.79	15,702,072.96
Selling expenses	107,937,871.02	95,849,746.50
General and administrative expense	461,198,028.89	388,648,813.97
Research and development expenses	171,055,447.09	154,805,698.65
Finance costs	-118,911,951.41	-175,590,189.04
Including: Interest expenses		
Interest income		
Add: Other income	17,516,717.29	8,382,915.17
Investment income	92,466,069.82	125,173,458.57
(losses are expressed by “-”)		
Including: Income from investment		
in associates and joint ventures		
Gain on de-recognition of financial assets at amortized cost		
Foreign exchange gain		
(losses are expressed by “-”)		
Net exposure hedging gain		
(losses are expressed by “-”)		
Gain from fair value change	402,587,783.41	1,117,343,694.68
(losses are expressed by “-”)		

Item	Amount for the period	Amount for the prior period
Credit impairment loss (losses are expressed by “-”)	-18,423,588.03	-6,071,755.06
Asset impairment loss (losses are expressed by “-”)	-26,587,375.66	-11,726,611.79
Gain on disposal of assets (losses are expressed by “-”)	-24,769.40	-567,076.49
III. Operating profit (losses are expressed by “-”)	2,001,007,232.46	2,340,841,785.80
Add: Non-operating income	11,032,473.26	2,433,020.50
Less: Non-operating expenses	6,038,596.06	7,371,450.82
IV. Total profits (total losses are expressed by “-”)	2,006,001,109.66	2,335,903,355.48
Less: Income tax expenses	233,766,699.72	150,182,232.76
V. Net profits (net losses are expressed by “-”)	1,772,234,409.94	2,185,721,122.72
(I) Classified by continuing operations		
1. Net profits from continuing operations (net losses are expressed by “-”)	1,772,234,409.94	2,185,721,122.72
2. Net profits from discontinued operations (net losses are expressed by “-”)		
(II) Classified by ownership of equity		
1. Net profits attributable to shareholders of the parent (net losses are expressed by “-”)	1,604,658,753.47	1,781,050,132.72
2. Non-controlling interests (net losses are expressed by “-”)	167,575,656.47	404,670,990.00
VI. Other comprehensive income, net of tax	350,582,272.99	-33,199,419.30
Other comprehensive income attributable to owners of the parent, net of tax	264,961,393.93	-21,775,456.44
(I) Items that will not be reclassified subsequently to profit or loss	8,401,565.65	
1. Changes arising from re-measurement of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss		
3. Change in fair value of other equity instruments investment	8,401,565.65	
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the period	Amount for the prior period
(II) Items that may be reclassified to profit or loss	256,559,828.28	-21,775,456.44
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investments		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investments		
5. Cash flow hedge reserve		
6. Currency translation difference	256,559,828.28	-21,775,456.44
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	85,620,879.06	-11,423,962.86
VII. Total comprehensive income	2,122,816,682.93	2,152,521,703.42
(I) Total comprehensive income attributable to owners of the parent	1,869,620,147.40	1,759,274,676.28
(II) Total comprehensive income attributable to non-controlling interests	253,196,535.53	393,247,027.14
VIII. Earnings per share:		
(I) Basic earnings per share	1.86	2.05
(II) Diluted earnings per share	1.86	2.04

For the business combination under common control in the current period, the net profit realized by the acquiree before the combination was RMB0.00, and the net profit realized by the acquiree in the prior period was RMB0.00.

<i>Legal representative:</i>	<i>Person-in-charge of accounting:</i>	<i>Head of accounting department:</i>
Cao Xiaochun	Yang Chengcheng	Yang Chengcheng

3. Consolidated cash flow statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	4,990,906,039.78	3,132,970,902.71
Net increase in customer deposits and placements from other banks		
Net increase in due to central bank		
Net increase in borrowings from other financial institutions		
Cash from premiums on original insurance contracts		
Cash received from reinsurance business, net		
Net increase in insured's deposits and investments		
Cash received from interest, fees and commissions		
Net increase in placements from banks and other financial institutions		
Net increase of funds in repurchase business		
Net cash received from customer brokerage		
Tax refunds	32,373,308.22	2,618,411.84
Cash receipts related to other operating activities	224,944,885.79	214,012,798.66
Sub-total of cash inflows from operating activities	5,248,224,233.79	3,349,602,113.21
Cash paid for goods and services	1,862,797,455.59	831,977,663.88
Net increase in loans and advances to customers		
Net increase in deposits with central bank and other banks		
Cash paid for claim settlements on original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employee benefits	1,881,767,190.45	1,294,418,520.76
Payments of all types of taxes	469,879,774.59	267,555,487.40
Cash payments related to other operating activities	208,394,582.29	227,241,027.68
Sub-total of cash outflows from operating activities	4,422,839,002.92	2,621,192,699.72
Net cash flows from operating activities	825,385,230.87	728,409,413.49

Item	Amount for the period	Amount for the prior period
II. Cash flows from investing activities:		
Cash received from sale of investments	349,399,581.69	969,256,266.54
Cash receipts from returns on investments	4,447,353.09	19,689,079.81
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	57,515.85	349,862.58
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities	88,957,429.07	41,765,189.23
Sub-total of cash inflows from investing activities	442,861,879.70	1,031,060,398.16
Cash paid to acquire fixed assets, intangible assets and other long-term assets	323,112,688.28	269,108,019.61
Cash paid for investments	1,852,295,982.67	3,003,490,442.16
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business units	678,094,308.93	18,861,100.00
Cash payments related to other investing activities		1,000,916.78
Sub-total of cash outflows from investing activities	2,853,502,979.88	3,292,460,478.55
Net cash flows from investing activities	-2,410,641,100.18	-2,261,400,080.39
III. Cash flows from financing activities:		
Cash receipts from capital contributions	333,083,314.14	263,486,616.54
Including: Cash receipts from capital contributions from noncontrolling interests of subsidiaries	311,400,000.00	236,400,500.00
Cash received from borrowings	2,620,373,982.50	300,000,000.00
Cash receipts related to other financing activities		12,671,961.00
Sub-total of cash inflows from financing activities	2,953,457,296.64	576,158,577.54
Cash repayments for debts	960,000,000.00	
Cash payments for distribution of dividends, profits or interest expenses	464,205,147.68	283,250,732.93
Including: Dividends and profits paid to non-controlling interests by subsidiaries	9,181,503.91	21,077,138.88
Cash payments related to other financing activities	735,484,878.29	439,196,871.84
Sub-total of cash outflows from financing activities	2,159,690,025.97	722,447,604.77
Net cash flows from financing activities	793,767,270.67	-146,289,027.23
IV. Effect of foreign exchange rates changes on cash and cash equivalents	97,337,754.63	-23,143,694.36
V. Net increase in cash and cash equivalents	-694,150,844.01	-1,702,423,388.49
Add: Cash and cash equivalents at the beginning of the period	8,378,417,680.06	9,959,963,262.81
VI. Cash and cash equivalents at the end of the period	7,684,266,836.05	8,257,539,874.32

(II) AUDIT REPORT

Whether the third quarterly report is audited

☐ Yes ☒ No

The third quarterly report of the Company is unaudited.

The Board of Directors of Hangzhou Tigermed Consulting Co., Ltd.

October 25, 2022

This report was originally prepared in Chinese. In the event of discrepancies between the Chinese and English versions, the Chinese version shall prevail.